- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04994158
MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis (MASCOT-R)
Myeloproliferative Neoplasms Associated SplanChnic Vein Thrombosis: Mascot Registry
Study Overview
Status
Intervention / Treatment
Detailed Description
Splanchnic or abdominal vein thrombosis (SVT) comprises thrombosis of hepatic, portal, superior mesenteric, splenic vein in isolation or combination. It has a prevalence of 1-2% in the general population based on autopsy reports. However, 40-50% of patients with hepatic vein thrombosis and about 25-30% of patients with PVT have an underlying myeloproliferative disease that is the cause of the thrombosis. Although some data on MPN-SVT have been published from European registries, the lack of sufficient clinical and scientific data in these patients has led to variation in treatment patterns with regard to timing, choice and duration of anticoagulation, the use of cytotoxic or biologic agents and interventions with thrombolysis and stenting with TIPSS in the acute stage. Data on the patterns of treatment of these patients in U.K and their outcomes with regard to morbidity and mortality are lacking. Availability of such data in U.K. will lead to the design of good quality prospective interventional studies.
PROJECT DESIGN This registry is designed for longitudinal real-world data collection on UK patients with MPN-SVT who are managed at tertiary liver centres in U.K. A pre-defined data set, built by a committee of specialist clinicians from the Mascot registry investigators will be collected and entered into the electronic web-based database built by Dendrite Clinical Systems Ltd.
The data captured includes demographic information linked to the NHS number, which will enable linked-anonymous data accrual and analysis as well as correlation with the Systemic Anti-Cancer Therapy Data Set (SACT) via the National Cancer Registration and Analysis Service (NCRAS) and Cancer Drug Fund (CDF) database. It will also allow interrogation of the national registries for stroke (SSNAP) and cardiac surgery (NACSA) as co-morbidities involving arterial circulation are prevalent in 30% of patients.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, NW3 2QG
- Royal Free London Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age>18 years
- Myeloproliferative neoplasm (MPN, WHO 2008, WHO 2016, BCSH) and splanchnic vein thrombosis
- Isolated Jak2v617f allele and splanchnic vein thrombosis
- MPN and portal cavernoma
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
transformation of MPN
Time Frame: 5 years
|
transformation to Myelofibrosis or leukaemia
|
5 years
|
progression of liver disease
Time Frame: 5 years
|
progression of liver disease
|
5 years
|
thrombosis events
Time Frame: 5 years
|
new or recurrent or improvement of thrombosis
|
5 years
|
haemorrhage events
Time Frame: 5 years
|
haemorrhage
|
5 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRAS 261989
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloproliferative Neoplasm
-
Sociedad de Lucha Contra el Cáncer del EcuadorCompletedMyeloproliferative Disorders | Myeloproliferative Neoplasm | Myeloproliferative Syndrome | Myeloproliferative Neoplasm, Unclassifiable | Myeloproliferative Disease, Not ClassifiedEcuador
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaAnemia | Myelofibrosis | Myelodysplastic/Myeloproliferative NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedMyelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise SpecifiedUnited States
-
Astex Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative NeoplasmUnited States, Canada
-
ImmunoGen, Inc.Active, not recruitingBlastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative NeoplasmUnited States, Spain, Germany, Italy, France, United Kingdom
-
Fred Hutchinson Cancer CenterImmunoGen, Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Mixed Phenotype Acute LeukemiaUnited States
-
BeiGeneRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Myelodysplastic/Myeloproliferative NeoplasmChina, United States, Australia, Spain, Korea, Republic of, New Zealand, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative NeoplasmUnited States
-
University of California, IrvineCompletedMyeloproliferative NeoplasmUnited States
-
Fondazione per la Ricerca Ospedale MaggioreCompletedMyeloproliferative NeoplasmItaly, United Kingdom, Germany, France, United States, Spain, Canada
Clinical Trials on Drugs, procedures
-
Duke UniversityTerminatedPre-Eclampsia | Neurocognitive DysfunctionUnited States
-
University of Missouri-ColumbiaRecruitingBreast Cancer FemaleUnited States
-
Prof.dr. E.G.E. de VriesRecruitingMelanoma | Non-Small Cell Lung CancerNetherlands
-
VA Office of Research and DevelopmentAugusta UniversityNot yet recruitingAge-related Macular Degeneration (AMD)United States
-
Rochester General HospitalActive, not recruitingNasopharyngeal Colonization and Acute Otitis MediaUnited States
-
Fondazione GISE OnlusUniversity of Padova; Shockwave Medical, Inc.; INNOVA HTS SRLRecruitingCoronary DiseaseItaly
-
University of Roma La SapienzaAzienda Ospedaliera Città della Salute e della Scienza di Torino; IRCCS Azienda... and other collaboratorsUnknownPneumonia, Viral | Covid19 | Obesity, Morbid | Complication of Surgical Procedure | Bariatric Surgery Candidate | Safety Issues | Readmission | Viral InfectionItaly
-
Medtronic - MITGCompletedChronic Inflammatory Small Bowel DiseaseIsrael
-
National Center for Occupational Health and Infection...VA Office of Research and DevelopmentCompletedTolerability | ComfortUnited States
-
University of Sao Paulo General HospitalRecruitingSARS-CoV2 Infection | Viral Load | Oral Diseases | Dental TreatmentBrazil